# NRC Health to Report Second Quarter 2026 Financial Results on July 28th
Canonical URL: https://biopharmsignal.com/news/NRC/nrc-health-to-report-second-quarter-2026-financial-results-on-july-28th-20318285
Ticker: NRC
Company: National Research Corporation
Source: National Research Corporation
Published: 2026-07-07 12:00 EST
Original Source URL: https://nrchealth.com/news/
## Summary

NRC Health (Nasdaq: NRC) will release its financial results for the second quarter on Tuesday, July 28, 2026.

## Article Body
LINCOLN, Neb., July 7, 2026 – NRC Health (Nasdaq: NRC), a leader in healthcare experience improvement solutions, today announced it will release its financial results for the second quarter ended June 30, 2026, on Tuesday, July 28, 2026, at approximately 4:00 p.m. Eastern Time. The second quarter 2026 results will be posted on the NRC Health Investor Relations website at https://nrchealth.com/investor-relations/ .

NRC Health CEO Trent Green and CFO Shane Harrison will host a conference call to discuss the financial results on Tuesday, July 28, 2026, at 4:30 p.m. Eastern Time. A live webcast link and call replay details will be available on the NRC Health Investor Relations website at https://nrchealth.com/investor-relations/ .

For more than 45 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know the patients, families, consumers, employees, and communities they serve on a human level. Guided by its uniquely empathic heritage, human-centered approach, unmatched national market research, and emphasis on consumer preferences, NRC Health is transforming the healthcare experience, creating strong outcomes across the healthcare journey. For more information, email [email protected] , or visit www.nrchealth.com.
## Recent Company News
- 2026-07-07 12:00 EST — [NRC Health to Report Second Quarter 2026 Financial Results on July 28th](https://biopharmsignal.com/news/NRC/nrc-health-to-report-second-quarter-2026-financial-results-on-july-28th-20318285) — Source: National Research Corporation
- 2026-06-17 06:58 EST — [The Top Women Leaders of Nebraska for 2026 - Women We Admire](https://biopharmsignal.com/news/NRC/the-top-women-leaders-of-nebraska-for-2026-women-we-admire-ede11cd4) — Source: National Research Corporation
- 2026-06-09 13:26 EST — [NRC Health and Healthcare Experience Foundation Launch Strategic Partnership to Deepen Support for Improving Experience, Safety, and Workforce Engagement](https://biopharmsignal.com/news/NRC/nrc-health-and-healthcare-experience-foundation-launch-strategic-partnership-to--220fd33f) — Source: National Research Corporation
- 2026-05-26 15:12 EST — [NRC Health Brings Ambient Listening With Agentic AI to the Front Lines of Leader Rounding](https://biopharmsignal.com/news/NRC/nrc-health-brings-ambient-listening-with-agentic-ai-to-the-front-lines-of-leader-e0d7759e) — Source: National Research Corporation
- 2026-05-11 00:00 EST — [Facing financial headwinds, health systems prioritize patient loyal...](https://biopharmsignal.com/news/NRC/facing-financial-headwinds-health-systems-prioritize-patient-loyal-378b16df) — Source: National Research Corporation
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)